128
Participants
Start Date
July 13, 2022
Primary Completion Date
April 17, 2025
Study Completion Date
April 17, 2025
ADCT-601
Intravenous (IV) infusion
Gemcitabine
Intravenous (IV) infusion
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario Madrid Sanchinarro, Madrid
Institut Bergonié, Bordeaux
Vanderbilt University Medical Center (VUMC) - Ingram Cancer Center, Nashville
University of IOWA, Iowa City
Washington University School of Medicine, St Louis
Institut Léon Bérard, Lyon
Sarah Cannon at University of Oklahoma Health Sciences Center, Oklahoma City
Sarcoma Oncology Research Center, Santa Monica
Stanford Cancer Center, Stanford Medicine at Stanford University, Stanford
Centre Antoine Lacassagne, Nice
Hospital Universitario Vall d'Hebron, Barcelona
The Royal Marsden NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
ADC Therapeutics S.A.
INDUSTRY